Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CLVS
CUSIP18946410
Phone303-625-5000
Debt
Debt-to-Equity Ratio1.84
Current Ratio10.03
Quick Ratio9.21
Price-To-Earnings
Trailing P/E Ratio-6.88
Forward P/E Ratio-5.21
P/E GrowthN/A
Sales & Book Value
Annual Sales$55.51 million
Price / Sales33.43
Cash FlowN/A
Price / CashN/A
Book Value$7.50 per share
Price / Book4.70
Profitability
EPS (Most Recent Fiscal Year)($5.12)
Net Income$-346,390,000.00
Net Margins-382.83%
Return on Equity-94.28%
Return on Assets-38.02%
Miscellaneous
Employees360
Outstanding Shares52,650,000
Market Cap$1.83 billion
Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions
What is Clovis Oncology's stock symbol?
Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."
How were Clovis Oncology's earnings last quarter?
Clovis Oncology (NASDAQ:CLVS) announced its quarterly earnings data on Wednesday, August, 1st. The biopharmaceutical company reported ($1.94) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.38) by $0.56. The biopharmaceutical company earned $23.76 million during the quarter, compared to analyst estimates of $22.44 million. Clovis Oncology had a negative net margin of 382.83% and a negative return on equity of 94.28%. Clovis Oncology's revenue was up 62.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.29) earnings per share. View Clovis Oncology's Earnings History.
When is Clovis Oncology's next earnings date?
What price target have analysts set for CLVS?
13 brokerages have issued 12-month price targets for Clovis Oncology's shares. Their predictions range from $55.52 to $110.00. On average, they expect Clovis Oncology's share price to reach $83.0578 in the next year. This suggests a possible upside of 135.6% from the stock's current price. View Analyst Price Targets for Clovis Oncology.
What is the consensus analysts' recommendation for Clovis Oncology?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clovis Oncology.
What are Wall Street analysts saying about Clovis Oncology stock?
Here are some recent quotes from research analysts about Clovis Oncology stock:
- 1. Cann analysts commented, "The initiation of the ATHENA study for the combination of a check point inhibitor with a PARP inhibitor for maintenance treatment of ovarian cancer could support increased use of Rubraca in this setting. Importantly, the participation of the prestigious cooperative groups, ENGOT and GOG, could expedite the study and will increase its impact when completed. GOG and ENGOT are the two largest cooperative groups in the US and Europe dedicated to the treatment of gynecological cancers. Based on the timing of the study, we are not making any changes to our outlook at this time." (8/8/2018)
- 2. According to Zacks Investment Research, "Clovis’ Rubraca is progressing well and registering sales growth. Nonetheless, Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Moreover, Clovis received approval for the label expansion in second-line maintenance setting in the United States, irrespective of BRCA-mutation, and as monotherapy in Europe. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. The company has stopped development of rociletinib upon receiving a CRL and lucitanib on negative results. Any further setback will adversely affect the company’s prospects. Moreover, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Meanwhile, Rubraca is set to face intense competition from currently marketed PARP inhibitors. Clovis’ shares have underperformed the industry so far this year." (7/10/2018)
Who are some of Clovis Oncology's key competitors?
Some companies that are related to Clovis Oncology include SAGE Therapeutics (SAGE), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), FibroGen (FGEN), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE) and GW Pharmaceuticals PLC- (GWPH).
Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the folowing people:
- Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
- Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
- Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
- Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
- Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)
Has Clovis Oncology been receiving favorable news coverage?
News stories about CLVS stock have trended somewhat negative on Monday, according to Accern Sentiment. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Clovis Oncology earned a news impact score of 0.00 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 47.27 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Clovis Oncology.
Who are Clovis Oncology's major shareholders?
Clovis Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Redmile Group LLC (3.34%), Macquarie Group Ltd. (1.31%), Jennison Associates LLC (1.31%), Voya Investment Management LLC (1.22%), Emerald Advisers Inc. PA (0.68%) and Emerald Mutual Fund Advisers Trust (0.56%). Company insiders that own Clovis Oncology stock include Gillian C Ivers-Read, James C Blair and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.
Which major investors are selling Clovis Oncology stock?
CLVS stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Tocqueville Asset Management L.P., C WorldWide Group Holding A S, Gabelli Funds LLC, California Public Employees Retirement System, Alps Advisors Inc., Alps Advisors Inc. and Alps Advisors Inc.. Company insiders that have sold Clovis Oncology company stock in the last year include Gillian C Ivers-Read and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.
Which major investors are buying Clovis Oncology stock?
CLVS stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, Voya Investment Management LLC, Macquarie Group Ltd., Sivik Global Healthcare LLC, Advisors Asset Management Inc. and Fred Alger Management Inc.. View Insider Buying and Selling for Clovis Oncology.
How do I buy shares of Clovis Oncology?
Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clovis Oncology's stock price today?
One share of CLVS stock can currently be purchased for approximately $35.25.
How big of a company is Clovis Oncology?
Clovis Oncology has a market capitalization of $1.83 billion and generates $55.51 million in revenue each year. The biopharmaceutical company earns $-346,390,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Clovis Oncology employs 360 workers across the globe.
How can I contact Clovis Oncology?
Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at bburka[email protected]
MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe CLVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
